CClinicalTrials.gg
CompletedNCT02478983Updated Jan 28, 2022

A Randomized Comparison of LMA (Laryngeal Mask Airway) Supreme and LMA Proseal in Infants Below 10kg

An interventional study of LMA Supreme and LMA Proseal in Laryngeal Mask Airway, sponsored by University of Malaya. Completed at 1 site in Malaysia. Open to participants aged 2 Months to 2 Years. Per ClinicalTrials.gov, last updated 2022-01-28.

Sponsored by University of Malaya · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
2 Months to 2 Years
Sex
All
01

Study summary

The investigators conduct this study to evaluate the clinical efficacy of size 1 and 1.5 supreme LMA compared to proseal LMA for infants weighing \<10kg.

Read the detailed description

This is a randomized prospective study to compare the clinical efficacy and safety for size 1 and 1.5 LMA supreme and LMA Proseal. The airway leak pressure of these 2 devices will be compared and other parameters such as time to insertion, insertion success rate, fibreoptic glottic view and intraoperative complications will be recorded.

02

Conditions studied

  • Laryngeal Mask Airway
03

In context

Lead sponsor

University of Malaya is the lead sponsor of 280 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Weight of \< 10kg
  • ASA (American Society of Anesthesiologists) I-II
  • Infants undergoing elective surgery under general anaesthesia using supraglottic airway device.
  • Informed consent obtained from parents.

Exclusion criteria

Exclusion Criteria:

  • ASA III-IV and emergency surgery
  • Neonates and ex-premature babies with post conceptual age \<55 weeks.
  • Infants with history of difficult airway.
  • Infants with features of difficult intubation.
  • Active upper respiratory tract infection
  • Infants with pulmonary disease
  • Infants with history of gastroesophageal reflux disease
  • Infants with risks of regurgitation and aspiration.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    LMA Supreme

    1 arm will receive LMA supreme for airway management

    Device: LMA Supreme

  • Active comparator
    LMA Proseal

    1 arm will receive LMA Proseal for airway management

    Device: LMA Proseal

Interventions

  • DeviceLMA Supreme

    The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.

  • DeviceLMA Proseal

    The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.

06

What researchers measure

Primary outcomes

  1. Oropharyngeal leak pressure

    The measurement of oropharyngeal airway pressure when airway leak occurred

    Time frame: intraoperative

Secondary outcomes

  1. Insertion success rate

    The number of attempts for successful placement of the supraglottic airway is recorded.

    Time frame: intraoperative

  2. Fibreoptic glottis view

    Fibreoptic glottis view will be recorded according to a grading system

    Time frame: intraoperative

  3. Intraoperative complications

    Complications such as loss of airway patency, desaturation, regurgitation of gastric contents, laryngospasm, bronchospasm and airway trauma will be recorded

    Time frame: intraoperative

  4. Time to insertion

    Time from picking up the supraglottic airway device to the first detection of capnography square wave

    Time frame: intraoperative

07

Study locations

1 site
  • Faculty of Medicine, University of Malaya
    Kuala Lumpur, Wilayah Persekutuan 50603, Malaysia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02478983
Lead sponsor
University of Malaya
Responsible party
Chaw Sook Hui (Dr., University of Malaya) — Principal investigator
First posted
Jun 23, 2015
Start date
Jun 2014
Primary completion
May 2016
Completion
May 2016
Last update
Jan 28, 2022

Study contacts

Sook Hui Chaw, M.Med
principal investigator · University of Malaya

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion